This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Picken, M. M. Articles by Gallo, G. Search for Related Content PubMed PubMed Citation Articles by Picken, M. M. Articles by Gallo, G.

American Journal of Pathology, Vol 134, 749-754, Copyright © 1989 by American Society for Investigative Pathology

REGULAR ARTICLES

Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization

MM Picken, B Frangione, B Barlogie, M Luna and G Gallo
Department of Pathology, New York University Medical Center, New York 10016.

The authors biochemically analyzed the nonamyloidotic light chain deposits, the first studied in this way, from a patient with systemic kappa light chain deposition disease (LCDD). The light chain deposits from myocardium were extracted in 6 M guanidine-HCl under reducing conditions, partially purified by column chromatography, and analyzed by immunoblotting and amino-terminal sequencing. The extracted material contained four main bands reactive with anti-kappa antibody: intact kappa light chain (MW, 28 kd), under reducing conditions, and 3 fragments (MW, 20, 16, and 15 kd). As revealed by the aminoterminal sequencing performed on three of the four bands, the intact light chain molecule and two fragments belong to the kappa I subgroup. Thus, similar to light chain amyloid (AL), the deposits in LCDD are derived from both intact light chain and fragments. Unlike in AL, amyloid P component was not detected in the deposits of this patient or those examined previously. The differences demonstrated thus far between AL and LCDD are the lack of fibrils and amyloid P component in LCDD, suggesting that local tissue factors may be responsible for different processing of the light chain deposits in LCDD.